FXN protein therapy (CTI-1601, also named Nomlabofusp) is in a phase II clinical trial (https://clinicaltrials.gov, accessed on 1 August 2024) for FRDA patients, who manifest peripheral nerve and central nerve disorders. Here, FXN is linked to Friedreich ataxia.